Institute Group Leaders awarded promotions by the University

We are delighted to announce that several of our Group Leaders have been promoted in the University of Cambridge Senior Academic Promotions.
James Brenton, Sarah Bohndiek and Doug Winton have been promoted to Professors, while Florian Markowetz and Nitzan Rosenfeld have been promoted to Directors of Research. All promotions will take effect from 1 October 2020.
James Brenton
Dr James Brenton has been promoted to Professor of Ovarian Cancer Medicine in the Department of Oncology. Brenton’s research focuses on understanding the molecular complexity of ovarian cancer to improve treatment and patient outcome.
Sarah Bohndiek
Dr Sarah Bohndiek has been promoted to Professor of Biomedical Physics in the Department of Physics. Her group focuses on developing novel imaging approaches that can be applied to understand the role of the tumour microenvironment in cancer progression.
Doug Winton
Dr Doug Winton has been promoted to Professor of Epithelial Biology in the Department of Oncology. His team investigates the cancer cells in the intestinal epithelium to understand the probability of their survival and expansion at each stage and how this varies with different mutations.
Florian Markowetz
Dr Florian Markowetz has been promoted to Director of Research. His team develops computational methods to link genomic profiles with quantitative measures of phenotypes, leading towards a comprehensive systems genetics understanding of cancer.
Nitzan Rosenfeld
Dr Nitzan Rosenfeld has been promoted to Director of Research. Nitzan’s expertise is in liquid biopsy and translational cancer research. His research group has established applications of circulating tumour DNA (ctDNA) sequencing to analyze ctDNA from blood samples of cancer patients.
Related News
See all news-
Sir Shankar Balasubramanian elected Fellow of the AACR Academy
10th March 2025
Sir Shankar has been recognised for his pioneering research in nucleic acid chemistry and his key role in the development of next-generation sequencing technology.
Find out more -
Richard Mair joins Institute as an Independent Clinical Fellow
10th February 2025
Richard will build a research group at the Institute to focus on IDH mutant astrocytoma, , a common type of brain tumour that accounts for 9% of brain tumour diagnoses.
Find out more -
Imaging technique allows rapid assessment of ovarian cancer subtypes and their response to treatment
6th December 2024
An MRI-based imaging technique developed at the Institute predicts the response of ovarian cancer tumours to treatment, and rapidly reveals how well treatment is working, in patient-derived cell models.
Find out more